Dr. Michael L. Grossbard, MD

Dr. Grossbard practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Dr. Grossbard's NPI, 1740263276, was assigned on November 29, 2005. Dr. Grossbard graduated from Yale School of Medicine in 1986. Dr. Grossbard holds New York license 216357.

Dr. Grossbard's primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Dr. Grossbard's primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. Dr. Grossbard is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Grossbard to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Grossbard practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Grossbard's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Grossbard is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Grossbard's licenses on file in 3 states: New York, Florida and Massachusetts.

Dmand AI lists anemia, chronic leukemia, lymphoma, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Grossbard treats.

CMS data shows 691 Medicare services from Dr. Grossbard across 6 procedure codes in 2024, for 304 Medicare patients. Medicare paid $56,104 for them.

CMS counts 304 Medicare patients who saw Dr. Grossbard in 2024. The largest group is 75 to 84, with 140 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Grossbard's median patient age at 71, with 46% women.

In 2024, Dr. Grossbard wrote 168 Medicare Part D claims for 49 patients. 85% of them were for generic drugs. CMS names the drug for 47 of them, across 3 drugs with 11 or more claims each, at $552 in total drug cost. In 2023, CMS named 71 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Grossbard for performance year 2024, reported as part of a group. Dr. Grossbard accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Grossbard as offering telehealth.

Dmand AI links 100 papers to Dr. Grossbard, published from 2004 to 2024. 2015 was the busiest year, with 9. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal and Lymphoma, B-Cell. Dr. Grossbard has published most often in J Clin Oncol. Dr. Grossbard's most frequent co-authors are Louis B. Harrison, MD, Peter S. Kozuch, MD and Joachim Yahalom, MD.

Dmand AI links Dr. Grossbard to 2 clinical trials. Conditions studied include Hodgkin Disease, HIV Infections and Lymphoma, Non-Hodgkin.

CMS Open Payments shows 5 general payments to Dr. Grossbard from 3 drug and device companies from 2016 to 2021. Consulting fees make up the largest share, 91% of the total. Merck Sharp & Dohme Corporation paid the most, $350.

Dmand AI lists 20 awards for Dr. Grossbard, most recently Top Doctors: New York Metro Area in 2019.

Dr. Grossbard graduated from Yale School of Medicine in 1986. Dr. Grossbard is a member of ASCO and ASH.

Dr. Grossbard is in network with 19 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 13. Check the plan with the practice before a visit.